In breast cancer, the HER2 gene is amplified in 20–30% of primary tumors; this amplification and resulting overexpression of HER2 protein are correlated with enhanced activity in signaling pathways involved in potent proliferative and antiapoptotic signals [10,11]. This evidence concerns the gene ERBB2 and breast carcinoma.